The research team enrolled 131 women who were scheduled to undergo surgery for breast conditions spanning the full spectrum of disease severity: 23 women with benign breast disease, 47 with high-risk or non-invasive lesions, and 61 with invasive breast cancer. The median age of participants was 59 years. Before any surgical intervention, each participant provided a preoperative stool sample, giving the investigators a snapshot of the gut microbial community in a window when the disease status was known but treatment had not yet altered the biology being measured. This design allowed the researchers to compare microbial profiles across diagnostic categories while also testing how body size influenced those profiles.

Technically, the study relied on shallow shotgun metagenomic sequencing, an approach that sequences the collective genomes of all microbes present in a sample rather than targeting a single marker gene. Taxonomic profiling was carried out with Sourmash version 4.2.4 against the GTDB v207 reference database, a comprehensive and evolutionarily consistent catalog of bacterial and archaeal genomes. Functional profiling was performed using HUMAnN 3.6, which maps detected gene families onto MetaCyc metabolic pathways. This dual strategy is important because knowing which species are present does not necessarily reveal what those microbes are doing; by interrogating the functional gene content, the team could ask whether the metabolic capabilities of the gut community shifted with body mass index independently of which particular organisms carried those genes.

The results revealed a clear signal tied to body size. Alpha diversity, a measure of how many distinct microbial species coexist within a single individual and how evenly they are distributed, differed across the three diagnosis groups and inversely correlated with increasing body mass index, with the Inverse Simpson index reaching statistical significance at p equal to 0.025. In practical terms, women with higher BMI tended to harbor less diverse gut communities, a pattern consistent with prior observations that obesity is associated with a contraction of microbial richness. Beta diversity, which quantifies differences in community composition between individuals, also varied significantly by both diagnosis group and BMI, indicating that the overall architectural layout of the gut ecosystem shifted along both axes.

Notably, the study found no significant differences in microbial diversity based on age, menopausal status, or mammographic breast density. This last finding is particularly interesting because breast density is itself a well-established breast cancer risk factor, and some investigators have hypothesized that the gut microbiome might influence density through estrogen metabolism. The absence of a density signal in this cohort suggests that, at least in this population of women already undergoing breast surgery, body mass index may be the dominant host characteristic shaping the gut microbial landscape, overshadowing factors that have historically attracted more attention in the microbiome-breast cancer literature.

At the level of individual taxa, higher BMI was associated with enrichment of species belonging to three genera in particular: Dorea, Blautia, and Streptococcus. These are not obscure organisms. Blautia in particular has repeatedly surfaced in obesity research, including earlier work linking the genus to visceral fat accumulation in adults. Dorea has likewise been flagged in large taxonomic surveys of adiposity in American adults. The convergence of these findings across independent cohorts strengthens the case that these organisms are not random passengers but consistent companions of the obese metabolic state, possibly thriving on the altered nutrient availability, bile acid profiles, and inflammatory milieu that characterize excess adiposity.

The functional analysis proved even more provocative. When the researchers profiled microbial metabolic pathways, they found that higher BMI was associated with greater relative abundance of genes involved in NAD biosynthesis, folate metabolism, and aromatic amino acid metabolism. Each of these pathways has plausible connections to cancer biology. NAD is a cofactor indispensable for energy metabolism, DNA repair, and cell survival, and tumor cells are notoriously dependent on NAD-generating pathways; drugs targeting NAMPT, a key enzyme in the NAD salvage route, are under active investigation as cancer therapeutics. Folate metabolism is central to one-carbon chemistry and nucleotide synthesis, making it a classic target of chemotherapy. Aromatic amino acid metabolism encompasses the handling of tryptophan, tyrosine, and phenylalanine, and the kynurenine branch of tryptophan catabolism has been implicated in immunosuppression within the breast tumor microenvironment.

Perhaps the most conceptually striking result emerged when the team cross-referenced their most significant taxonomic and functional findings. That integrative analysis suggested that enrichment of Blautia species, acting through tryptophan metabolism, might provide a mechanistic bridge to the observed increase in NAD biosynthesis pathways. The logic is biologically coherent: certain gut bacteria can convert tryptophan into metabolites that feed into de novo NAD synthesis, and prior work has shown that bacteria can boost mammalian host NAD metabolism by engaging alternative biosynthesis routes. If the obesity-associated expansion of Blautia indeed channels more tryptophan-derived substrate into NAD-generating pathways, it could conceivably alter the systemic metabolic environment in ways that influence breast tissue biology, although the authors are careful to frame this as a hypothesis-generating observation rather than a demonstrated causal chain.

The study’s authors emphasize that these findings do not prove that the gut microbiome causes breast cancer, nor do they establish the direction of causality between BMI, microbial composition, and disease status. The cross-sectional design captures associations at a single time point, and the cohort consists of women already undergoing surgery for breast conditions, which may limit generalizability to healthy populations. Nevertheless, the work provides a concrete rationale for future longitudinal studies that could track whether obesity-associated microbial signatures precede malignant transformation, and whether interventions such as weight loss or dietary modification can reshape the gut microbiome in ways that reduce risk. Indeed, related ongoing research is already exploring how weight loss and omega-3 supplementation modulate the microbiome in women at increased breast cancer risk.

What makes this study resonate beyond the specialist literature is the way it reframes obesity as not merely a hormonal or inflammatory risk factor but also an ecological one. The human gut is a metabolic organ in its own right, and the microbes it hosts process dietary compounds, synthesize vitamins, regulate immune signaling, and metabolize estrogens that circulate to distant tissues including the breast. By documenting that body mass index leaves a detectable fingerprint on both the taxonomy and the functional repertoire of this internal ecosystem in women across the benign-to-malignant disease spectrum, the Mayo Clinic team has laid groundwork for a future in which microbiome profiles might one day help stratify breast cancer risk, or in which microbial pathways such as tryptophan-fueled NAD biosynthesis become targets for prevention strategies aimed at the interface between body weight and tumor biology.

Subject of Research: Associations between body mass index, gut microbial taxa, and microbial functional pathways in women with benign and malignant breast disease

Article Title: Body mass index-associated gut microbial taxa and functional pathways in women with benign and malignant breast disease

Article References: Sample, J. W., Johnson, S., Hoskin, T. L., Redaelli, M., Walther-Antonio, M. R., Chen, J., Degnim, A. C., & Hieken, T. J. (2026). Body mass index-associated gut microbial taxa and functional pathways in women with benign and malignant breast disease. Breast Cancer Research and Treatment, 219(2), Article 4. https://doi.org/10.1007/s10549-026-08065-6

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08065-6

Keywords: breast cancer, obesity, body mass index, gut microbiome, microbiome, Blautia, Dorea, Streptococcus, tryptophan metabolism, NAD biosynthesis, folate metabolism, breast density